Skip to content

Implementation of an Advanced Telerehabilitation Solution for People With Multiple Sclerosis

Implementation of an Advanced Telerehabilitation Solution for People With Multiple Sclerosis

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07310914
Acronym
PLATINUMS
Enrollment
94
Registered
2025-12-30
Start date
2026-02-01
Completion date
2027-07-01
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Neurorehabilitation, Telerehabilitation

Brief summary

The overall purpose of the present study is to investigate the effect of an advanced telerehablitation system (TRS) in persons with multiple sclerosis on mobility. The advanced telerhabilitation system is based on AI components, and delivers instant feedback to the partcipants. If the project is successful, it can help optimize exercise for those persons with multiple sclerosis who are either not able or willing to travel to a clinical setting for exericse.

Interventions

BEHAVIORALTelerehabilitation

Advanced telerehabilitation with a program made by specialized physiotherapists and delivered through the WizeCare system.

BEHAVIORALPaper-based exercise

Paper-based exercise instructions made by specialized physiotherapists.

Sponsors

MS Ireland
CollaboratorUNKNOWN
Tel Aviv University
CollaboratorOTHER
University of Cagliari
CollaboratorOTHER
University of Limerick
CollaboratorOTHER
Danish Multiple Sclerosis Hospitals
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Definite diagnosis of MS according to the McDonald criteria (both relapse-remitting and progressive) * Expanded Disability Status Scale (EDSS) score of 2.5 to 6.5 or Patient Determined Disability Score (PDDS) of 2 to 6, indicating preservation of at least some ambulatory function, that is, the ability to walk 20 meters or more, independently, with or without the use of an assistive device * Willingness to travel to the local study site for the evaluation sessions, * Internet platform availability

Exclusion criteria

* comorbidities hindering participation in the study. * Individuals who have had a documented relapse and/or corticoid treatment during the past three months will be excluded, * Individuals with severe cognitive deficits who cannot follow simple instructions and/or consent.

Design outcomes

Primary

MeasureTime frameDescription
30 second sit to stand testBaseline to 10 weeksMeasure of lower extremity muscle power and a proxy measure of mobility

Secondary

MeasureTime frameDescription
Functional Reach TestBaseline to 10 weeksA measure of stability
Timed 25 feet foot walk testBaseline to 10 weeksA measure of walking speed
MiniBESTestBaseline to 10 weeksA measure of balance
Six minute walk testBaseline to 10 weeksA measure of walking endurance
Modified Fatigue Impact ScaleBaselinePatient-reported measure of fatigue
12 item Multiple Sclerosis Walking ScaleBaseline to 10 weeksPatient-reported outcome of walking function
Multiple Sclerosis Impact ScaleBaseline to 10 weeksPatient-reported measure on the impact of multiple sclerosis
Short Physical Performance BatteryBaseline to 10 weeksMeaure of balance, walking function and lower extremity muscle strength
State-Trait Anxiety InventoryBaseline to 10 weeksPatient-reported measure of anxiety
Quick Inventory of Depression SymptomologyBaseline to 10 weeksPatient-reported measure of depressive symptoms
Client Services Receipt InventoryBaseline to 10 weeksPatient-reported measure of used health services
Digital Health Literacy ScaleBaselinePatient-reported measure of digital health literacy
Telehealth Usability Questionnaire10 weeksPatient-reported measure of telehealth usability
Semi-structed interview10 weeksA semi-structured interview on the satisfaction with the telerehabilitation system
EQ-5D-5LBaseline to 10 weeksPatient-reported measure of quality of life

Countries

Denmark, Ireland, Israel, Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026